http://www.streetinsider.com Latest StreetInsider.com News Articles en-us Copyright 2026, StreetInsider.com rss@streetinsider.com (SI RSS) rss@streetinsider.com (SI RSS) Mon, 13 Jul 2026 02:01:09 -0400 http://blogs.law.harvard.edu/tech/rss http://www.streetinsider.com/images/rss_logo.gif http://www.streetinsider.com 143 28 0 1 2 3 21 22 23 Saturday Sunday http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html <p>Celea Therapeutics, a company founded by PureTech Health plc (LSE: PRTC), has dosed the first patient in the global Phase 3 SURPASS-IPF trial, evaluating deupirfenidone for the treatment of idiopathic pulmonary fibrosis (IPF), according to a press release.</p> <p>The trial is described as the first industry-sponsored head-to-head Phase 3 study in IPF. It is a randomized, double-blind trial comparing deupirfenidone 825 mg three times daily to pirfenidone 801 mg three times daily over 52 weeks. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. The trial is expected to enroll approximately 1,100 adults across more http://www.streetinsider.com/FDA/Celea+Therapeutics+begins+Phase+3+trial+of+deupirfenidone+for+IPF/26758709.html Mon, 13 Jul 2026 02:01:09 -0400 A.06822034 A.26940647 A.27193410 A.37672378 A.50216916 A.60012002 A.60012004 A.60012014 O.00638181 O.00831932 O.01304637 O.05062066 O.20026344 O.22973220 O.56907606 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html <p>Celea Therapeutics, Inc. has dosed the first patient in its global Phase 3 SURPASS-IPF trial, which is evaluating deupirfenidone 825 mg three times daily against pirfenidone 801 mg three times daily for the treatment of idiopathic pulmonary fibrosis (IPF), according to a company statement.</p> <p>The trial is a randomized, double-blind, head-to-head study planned to enroll approximately 1,100 adults with IPF across more than 30 countries. The primary endpoint is change from baseline in absolute forced vital capacity at week 52. Topline results are expected in the second half of 2029.</p> <p>The trial does not include a placebo arm; all participants will receive http://www.streetinsider.com/FDA/Celea+Therapeutics+doses+first+patient+in+phase+3+IPF+drug+trial/26758705.html Mon, 13 Jul 2026 02:00:57 -0400 A.06822034 A.50216916 A.60012002 A.60012004 O.01304637 O.20026344 O.22973220 O.76898468 PRTC